Analyzing AML: novel therapies in review

preview_player
Показать описание
Farhad Ravandi-Kashani, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, shares key highlights, including trials, future outlooks, and progressions in the field of acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Farhad Ravandi
  3. Format: Interview
  4. Event: ASH 2018
  5. Subject: Leukemia
  6. Subject: Acute Myeloid Leukemia
Рекомендации по теме
From MDS to 0:34:15

From MDS to AML: What Every Patient Needs to Know 11/28/17

Acute Myeloid Leukemia: 0:18:23

Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 1

Acute Myeloid Leukemia: 0:52:20

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

AML diagnosis and 0:47:56

AML diagnosis and treatment 2022

Novel Investigational Drugs 0:21:27

Novel Investigational Drugs in AML What's the Data

Role of FLT3 0:20:29

Role of FLT3 Inhibitors and Other Novel Agents in AML

Measurable Residual Disease 0:22:56

Measurable Residual Disease (MRD) in AML and ALL

Why MPNs Transform 0:23:38

Why MPNs Transform to AML

Current AML landscape: 0:24:14

Current AML landscape: Where do we stand in 2018?

Webinar: Tapestri Platform 0:55:15

Webinar: Tapestri Platform Expansion for Hematologic Malignancy Research

Update: New Drugs 0:20:44

Update: New Drugs for AML

WSBS 2021 | 0:23:16

WSBS 2021 | Novel Therapies In Chordoma and Chondrosarcoma | Part 14

Acute Myeloid Leukemia 1:04:53

Acute Myeloid Leukemia (AML): Finally Making Progress? J. Zeidner - 20180523

Current and Future 0:37:46

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD

Targeting Stem Cell 0:13:45

Targeting Stem Cell Signals in Cancer Progression and Therapy Resistance - Tannishtha Reya

TP53-Mutant AML: A 0:23:04

TP53-Mutant AML: A Pathology-Guided Journey Through Diagnostic Principles

First-in-human phase I 0:11:06

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dex in pts with RRMM

Novel agents or 0:01:27

Novel agents or imatinib for CML in the frontline setting?

2019 Multiple Myeloma 0:44:44

2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy

Acute Myeloid Leukemia: 0:58:36

Acute Myeloid Leukemia: An Overview and Updates

MRD Monitoring in 0:50:49

MRD Monitoring in Acute Myeloid Leukemia

DEBATE: Follicular lymphoma 0:16:20

DEBATE: Follicular lymphoma patient with early progression - Autologous stem cell transplant

MRD in AML: 0:24:36

MRD in AML: What is it and what do I do about it?

Stem Cell Transplant 0:24:51

Stem Cell Transplant Approaches to MDS

join shbcf.ru